专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

51. 发明申请

US20190008988A1 LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), THEIR USE AS IMAGING AGENTS AND PHARMACEUTICAL AGENTS FOR THE TREATMENT OF PROSTATE CANCER 审中-公开
公开(公告)号：US20190008988A1
公开(公告)日：2019-01-10
申请号：US16038729
申请日：2018-07-18
申请人： DEUTSCHES KREBSFORSCHUNGSZENTRUM , RUPRECHT-KARLS-UNIVERSITÄT HEIDELBERG
发明人： Matthias EDER , Klaus KOPKA , Martin SCHÄFER , Ulrike BAUDER-WÜST , Uwe HABERKORN , Michael EISENHUT , Walter MIER , Martina BENESOVA , Hans-Christian KLIEM , Clemens KRATOCHWIL
IPC分类号： A61K51/04 , C07D257/02 , C07B59/00 , C07D295/145
摘要： The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of prostate cancer. Thus, the present invention concerns compounds that are represented by the general Formulae (Ia) or (Ib).

52. 发明申请

US20180354993A1 CYCLIC NTCP-TARGETING PEPTIDES AND THEIR USES AS ENTRY INHIBITORS 审中-公开
公开(公告)号：US20180354993A1
公开(公告)日：2018-12-13
申请号：US15780129
申请日：2016-12-15
申请人： Ruprecht-Karls-Universität Heidelberg
发明人： Stephan URBAN , Yi NI , Walter MIER
IPC分类号： C07K14/00 , A61P31/20
CPC分类号： C07K14/001 , A61K38/00 , A61K49/0056 , A61K51/088 , A61P31/20 , C07K7/06 , C07K7/08 , C07K7/50 , C07K7/64 , C07K14/005 , C12N2730/10111 , C12N2730/10141 , Y02A50/409 , Y02A50/411 , Y02A50/423 , Y02A50/463
摘要： The present invention relates to cyclic NTCP targeting peptides which are preS-derived peptides of hepatitis B virus (HBV). The present invention further relates to pharmaceutical compositions comprising at least one cyclic peptide. The present invention further relates to medical uses of said cyclic peptides and the pharmaceutical compositions, such as in the diagnosis, prevention and/or treatment of a liver disease or condition, and/or in the inhibition of HBV and/or HDV infection. The present invention further relates to methods of diagnosis, prevention and/or treatment of a liver disease or condition and/or the inhibition of HBV and/or HDV infection.

53. 发明申请

US20180334442A1 CHROMENE DERIVATIVES AND THEIR ANALOGS AS WNT PATHWAY ANTAGONISTS 审中-公开
公开(公告)号：US20180334442A1
公开(公告)日：2018-11-22
申请号：US16046578
申请日：2018-07-26
申请人： Deutsches Krebsforschungszentrum , Ruprecht-Karls-Universität Heidelberg
发明人： Michael BOUTROS , Rajendra-Prasad MASKEY , Corinna KOCH , Florian FUCHS , Sandra STEINBRINK , Daniel GILBERT
IPC分类号： C07D311/92 , C07D493/04 , C07D491/052 , C07D311/04 , C07D413/04 , C07D311/96 , C07D491/04
CPC分类号： C07D311/92 , C07D311/04 , C07D311/96 , C07D413/04 , C07D491/04 , C07D491/052 , C07D493/04
摘要： Compounds of formula (IIc); wherein X3 and X4 independently from each other are N or CR8 wherein R8 may be same or different; Y1, Y2, Y3 and Y4 independently from each other are N or CR9 wherein R9 may be same or different and wherein up to 3 of the group Y1, Y2, Y3 and Y4 may be N; their solvates, hydrates, and pharmaceutically acceptable salts, their use for modulating the Wnt signalling pathway activity and their use as a medicament, preferably for the treatment of cancer.

54. 发明申请

US20180221479A1 AGENTS FOR USE IN THE TREATMENT OF GLIOMA 审中-公开
公开(公告)号：US20180221479A1
公开(公告)日：2018-08-09
申请号：US15748537
申请日：2016-07-06
申请人： RUPRECHT-KARLS-UNIVERSITÄT HEIDELBERG , DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES ÖFFENTLICHEN RECHTS
发明人： Matthias Osswald , Wolfgang Wick , Frank Winkler , Erik Jung , Jonas Blaes
IPC分类号： A61K39/395 , A61K31/522 , A61P35/00
摘要： The present invention relates to agents for use in the treatment of glioma, in particular astrocytoma WHO IF and 111°, as well as IV0 (glioblastoma), in a subject.

55. 发明授权

US10041070B2 MicroRNAs modulating the effect of glucocorticoid signaling 有权
公开(公告)号：US10041070B2
公开(公告)日：2018-08-07
申请号：US15033442
申请日：2014-10-28
申请人： Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts , Ruprecht-Karls-Universität Heidelberg
发明人： Mauricio Berriel Diaz , Roldan De Guia , Stephan Herzig
IPC分类号： C12N15/113
摘要： The present invention discloses microRNAs (miR) involved in the regulation of the lipid and glucose metabolism. Several conserved miR molecules were found as direct targets of the glucocorticoid hormone/glucocorticoid receptor signaling axis. Hence, the present invention pertains to inhibitors of these miRs—such as antimiRs and blockmiRs—as well as isolated miR molecules or miR expression constructs for the treatment or prevention of metabolic disorders caused by deregulated glucocorticoid signaling, such as insulin resistance, the metabolic syndrome, obesity and/or diabetes type II. Particular preferred embodiments of the invention pertain to antagonists or agonists of a miR of the conserved miR-379-410 cluster, particularly of miR-379.

56. 发明申请

US20180110813A1 PARVOVIRUS FORMULATION FOR TREATING TUMORS 审中-公开
公开(公告)号：US20180110813A1
公开(公告)日：2018-04-26
申请号：US15830489
申请日：2017-12-04
申请人： DEUTSCHES KREBSFORSCHUNGSZENTRUM , RUPRECHT-KARLS-UNIVERSITÄT HEIDELBERG
发明人： Barbara Leuchs , Karsten Geletneky , Jean Rommelaere , Christiane Dinsart , Michael Dahm , Ottheinz Krebs
IPC分类号： A61K35/768 , A61P35/00 , A61K47/02 , A61K47/18 , A61K9/00
摘要： Described is a parvovirus formulation which comprises (a) at least 1×109 pfu/ml of parvovirus H1 (H-1PV) or a related rodent parvovirus such as LuIII, Mouse minute virus (MMV), Mouse parvovirus (MPV), Rat minute virus (RMV), Rat parvovirus or Rat virus (RV) and (b) a pharmaceutically acceptable carrier containing 40-50% Iodixanol (w/v), 0.7-0.9 mmol CaCl2 x 2 H2O, 50-60 mmol NaCl, 0.9-1.2 mmol KCl, 0.7-0.95 mg/ml Tromethamine and 0.05-0.15 mg/ml Edetate calcium disodium.. A preferred use is the therapy of a brain tumour by intratumoral injection.

57. 发明授权

US09487815B2 Means and methods for the determination of (D)-2-hydroxyglutarate (D2HG) or (D)-2-hydroxyadipic acid 有权
标题翻译：用于测定（D）-2-羟基戊二酸（D2HG）或（D）-2-羟基己二酸的方法和方法
公开(公告)号：US09487815B2
公开(公告)日：2016-11-08
申请号：US14381835
申请日：2013-03-01
申请人： DKFZ Deutsches Krebsforschungszentrum , Ruprecht-Karls-Universität Heidelberg
发明人： Jörg Balss , Stefan Pusch , Andreas Von Deimling , Wolfgang Buckel
IPC分类号： C12Q1/32 , G01N33/574
CPC分类号： C12Q1/32 , C12Q2326/00 , G01N33/57407 , G01N2333/904 , G01N2458/15 , G01N2800/046 , G01N2800/22 , G01N2800/28
摘要： The present invention relates to a method for detecting (D)-2-hydroxyglutarate or (D)-2-hydroxyadipic acid in a sample, the method comprising the steps of: a) contacting a sample with a reagent mixture, wherein said reagent mixture comprises: (i) a solvent, (ii) a dye having an oxidized state and a reduced state, wherein the reduced state can be distinguished from the oxidized state and wherein the dye is initially present in the oxidized state, (iii) an electron transfer agent, (iv) a (D)-2-hydroxyglutarate dehydrogenase enzyme, and (v) a cofactor; and b) detecting (D)-2-hydroxyglutarate or (D)-2-hydroxyadipic acid by measuring the production of the reduced state of the dye. The invention further pertains to a method for diagnosing and/or monitoring a (D)-2-hydroxy-glutarate-associated disease in a subject. Encompassed by the invention is also a method for diagnosing a mutation in an isocitrate dehydrogenase (IDH) gene or in a (D)-2-hydroxyglutarate (D2HG) dehydrogenase enzyme gene in a subject. In addition, the invention provides for a kit comprising (i) a solvent, (ii) a dye having an oxidized state and a reduced state, wherein the reduced state can be distinguished from the oxidized state and wherein the dye is initially present in the oxidized state, (iii) an electron transfer agent, (iv) a (D)-2-hydroxyglutarate dehydrogenase enzyme, and (v) a cofactor.
摘要翻译：本发明涉及一种用于检测样品中（D）-2-羟基戊二酸或（D）-2-羟基己二酸的方法，所述方法包括以下步骤：a）使样品与试剂混合物接触，其中所述试剂混合物包括：（i）溶剂，（ii）具有氧化态和还原状态的染料，其中还原态可以与氧化态区别，其中染料最初以氧化态存在，（iii）电子转移剂，（iv）（D）-2-羟基戊二酸脱氢酶，和（v）辅因子; 和b）通过测量染料的还原状态的产生来检测（D）-2-羟基戊二酸或（D）-2-羟基己二酸。本发明还涉及用于诊断和/或监测受试者中（D）-2-羟基 - 戊二酸酯相关疾病的方法。本发明所涉及的也是用于诊断受试者的异柠檬酸脱氢酶（IDH）基因或（D）-2-羟基戊二酸（D2HG）脱氢酶基因中的突变的方法。另外，本发明提供了一种试剂盒，其包含（i）溶剂，（ii）具有氧化态和还原状态的染料，其中还原态可以与氧化态区别，并且其中染料最初存在于氧化态，（iii）电子转移剂，（iv）（D）-2-羟基戊二酸脱氢酶，和（v）辅助因子。

58. 发明申请

US20160209433A1 MEANS AND METHODS FOR DIAGNOSING HEART FAILURE IN A SUBJECT 审中-公开
标题翻译：用于诊断主体心脏衰竭的手段和方法
公开(公告)号：US20160209433A1
公开(公告)日：2016-07-21
申请号：US14914815
申请日：2014-09-01
申请人： METANOMICS GMBH , RUPRECHT-KARLS-UNIVERSITÄT HEIDELBERG
发明人： Henning Witt , Juergen Kastler , Bianca Bethan , Erik Peter , Philipp Schatz , Hans Dirk Duengen , Tobias Daniel Trippel , Elvis Tahirovic , Hugo A. Katus , Norbert Frey , Tanja Weis
IPC分类号： G01N33/92 , G06F19/28
CPC分类号： G01N33/92 , G01N33/6893 , G01N2405/08 , G01N2560/00 , G01N2570/00 , G01N2800/325 , G16B50/00
摘要： The present invention relates to the field of diagnostic methods. Specifically, the present invention contemplates a method for diagnosing heart failure in a subject based on a group of biomarkers. The invention also relates to tools for carrying out the aforementioned methods, such as diagnostic devices.
摘要翻译：本发明涉及诊断方法领域。具体地，本发明考虑了一种用于基于一组生物标志物来诊断受试者的心力衰竭的方法。本发明还涉及用于执行上述方法的工具，例如诊断装置。

59. 发明申请

US20150044716A1 MEANS AND METHODS FOR THE DETERMINATION OF (D)-2-HYDROXYGLUTARATE (D2HG) OR (D)-2-HYDROXYADIPIC ACID 有权
标题翻译：用于测定（D）-2-羟基甘油（D2HG）或（D）-2-羟基乙酸的方法和方法
公开(公告)号：US20150044716A1
公开(公告)日：2015-02-12
申请号：US14381835
申请日：2013-03-01
申请人： DKFZ Deutsches Krebsforschungszentrum , Ruprecht-Karls-Universität Heidelberg
发明人： Jörg Balss , Stefan Pusch , Andreas Von Deimling , Wolfgang Buckel
IPC分类号： C12Q1/32
CPC分类号： C12Q1/32 , C12Q2326/00 , G01N33/57407 , G01N2333/904 , G01N2458/15 , G01N2800/046 , G01N2800/22 , G01N2800/28
摘要： The present invention relates to a method for detecting (D)-2-hydroxyglutarate or (D)-2-hydroxyadipic acid in a sample, the method comprising the steps of: a) contacting a sample with a reagent mixture, wherein said reagent mixture comprises: (i) a solvent, (ii) a dye having an oxidized state and a reduced state, wherein the reduced state can be distinguished from the oxidized state and wherein the dye is initially present in the oxidized state, (iii) an electron transfer agent, (iv) a (D)-2-hydroxyglutarate dehydrogenase enzyme, and (v) a cofactor; and b) detecting (D)-2-hydroxyglutarate or (D)-2-hydroxyadipic acid by measuring the production of the reduced state of the dye. The invention further pertains to a method for diagnosing and/or monitoring a (D)-2-hydroxy-glutarate-associated disease in a subject. Encompassed by the invention is also a method for diagnosing a mutation in an isocitrate dehydrogenase (IDH) gene or in a (D)-2-hydroxyglutarate (D2HG) dehydrogenase enzyme gene in a subject. In addition, the invention provides for a kit comprising (i) a solvent, (ii) a dye having an oxidized state and a reduced state, wherein the reduced state can be distinguished from the oxidized state and wherein the dye is initially present in the oxidized state, (iii) an electron transfer agent, (iv) a (D)-2-hydroxyglutarate dehydrogenase enzyme, and (v) a cofactor.
摘要翻译：本发明涉及一种用于检测样品中（D）-2-羟基戊二酸或（D）-2-羟基己二酸的方法，所述方法包括以下步骤：a）使样品与试剂混合物接触，其中所述试剂混合物包括：（i）溶剂，（ii）具有氧化态和还原状态的染料，其中还原态可以与氧化态区别，其中染料最初以氧化态存在，（iii）电子转移剂，（iv）（D）-2-羟基戊二酸脱氢酶，和（v）辅因子; 和b）通过测量染料的还原状态的产生来检测（D）-2-羟基戊二酸或（D）-2-羟基己二酸。本发明还涉及用于诊断和/或监测受试者中（D）-2-羟基 - 戊二酸酯相关疾病的方法。本发明所涉及的也是用于诊断受试者的异柠檬酸脱氢酶（IDH）基因或（D）-2-羟基戊二酸（D2HG）脱氢酶基因中的突变的方法。另外，本发明提供了一种试剂盒，其包含（i）溶剂，（ii）具有氧化态和还原状态的染料，其中还原态可以与氧化态区别，并且其中染料最初存在于氧化态，（iii）电子转移剂，（iv）（D）-2-羟基戊二酸脱氢酶，和（v）辅助因子。

60. 发明申请

US20220119332A1 PROCESS FOR THE PRODUCTION OF ACETALS FROM CARBON DIOXIDE 有权
公开(公告)号：US20220119332A1
公开(公告)日：2022-04-21
申请号：US17425805
申请日：2020-02-05
申请人： BASF SE , Ruprecht-Karls-Universität Heidelberg
发明人： Thomas Schaub , Ivana Jevtovikj , A. Stephen K. Hashmi , Kohei Sekine
IPC分类号： C07C41/50 , B01J31/18 , B01J31/22 , B01J31/24
摘要： The invention relates to a process for the preparation of acetals from carbon dioxide. The invention also relates to a mixture of phosphorus containing ligands comprising least one polydentate ligand and at least one monodentate ligand. Further, the invention also relates to the use of mixtures comprising at least one polydentate ligand and at least one monodentate ligand in transition metal complexes for the preparation of acetals.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式